Pembrolizumab as a First-Line Therapy in dMMR Advanced or Recurrent Endometrial Cancer: Insights from the KEYNOTE-C93 Phase 3 Trial

Highlight

• Pembrolizumab monotherapy significantly extends progression-free survival compared to carboplatin plus paclitaxel in dMMR advanced or recurrent endometrial cancer.
• Pembrolizumab shows a superior safety profile with fewer grade 3 or higher treatment-related adverse events.
• Overall survival benefit did not reach statistical significance at interim analysis.
• The trial establishes immunotherapy as a promising chemotherapy-free first-line option for this patient subset.

Study Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply